{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115303","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.291659+00:00","generated_at":"2026-05-30T03:23:29.289574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025","bullets":["Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.","Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.","License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.","Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.","Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115303","json":"https://secwatch.observer/filing/0001104659-24-115303.json","markdown":"https://secwatch.observer/filing/0001104659-24-115303.md","text":"https://secwatch.observer/filing/0001104659-24-115303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/0001104659-24-115303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/tm2427679d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:23:29.289574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}